NAD+ and its precursors (nicotinamide riboside, NMN) have a uniquely route-dependent adverse-event profile. The oral precursors have multiple published Phase 1 and small Phase 2 trials with clean safety profiles. Injectable NAD+ — the route community sources discuss most — has no equivalent trial dataset. Most of what users will encounter at a clinic or self-administered subcutaneously comes from clinic-published infusion protocols and self-reports.
Research-context information only. NAD+ and its precursors are research compounds and supplements. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
This article separates oral-precursor trial data (well-characterized) from IV and subcutaneous NAD+ adverse events (community-source-dominated), and walks through the dose-pause patterns described in research and community sources.
Oral Precursor Trial Data
The most rigorous human safety dataset for the NAD+ pathway is for nicotinamide riboside (NR).
Across these trials, oral NR at doses up to 2,000 mg/day produced an event profile dominated by mild gastrointestinal symptoms. No trial reported the flushing, chest pressure, or vagal symptoms that dominate IV NAD+ self-reports.
Note on labeling: the events below come from clinic-published infusion procedures and self-reported community sources. There is no Phase 2 or Phase 3 trial dataset for IV NAD+ administration in healthy adults at the doses typically used in research-peptide and wellness-clinic contexts.
Flushing
The most consistently described event during IV NAD+ infusion. Self-reported community timelines describe facial and chest flushing within the first 10-20 minutes of infusion, fading when the infusion is paused or slowed. The pattern is rate-dependent: faster infusions produce more pronounced flushing.
Chest pressure or tightness
Community reports cluster around a sensation of chest pressure or heaviness during the first 15-30 minutes of rapid infusion. The pattern resolves within minutes of slowing the infusion. Clinic-published protocols describe pausing the infusion until the sensation fades, then resuming at half the prior rate.
Nausea
The most consistent community feedback for nausea is during the first 20 minutes of infusion, fading within an hour. Self-reported community sources describe morning-administration timing reducing severity.
Vagal symptoms — lightheadedness, brief sweating
Less consistently reported. Community sources describe these symptoms accompanying high-rate infusions and resolving when the infusion is slowed.
Headache post-infusion
Sparse community reports describe a mild headache in the 2-12 hours following infusion, attributed by community sources to vasodilatory effects.
Subcutaneous NAD+ Self-Reported Adverse Events
Subcutaneous NAD+ injection is the dominant self-administered route in research-peptide community sources. Self-reported adverse events differ from the IV pattern:
Injection-site pain or burning — the most consistent community feedback. Users self-report it as more uncomfortable than typical subcutaneous peptide injection. Community sources commonly describe smaller volumes per site and slower injection speed.
Localized warmth at the injection site, fading by 30 minutes.
Brief flushing at higher per-injection doses — less pronounced than IV pattern.
The IV-route findings (chest pressure, rate-dependent nausea) do not transfer to subcutaneous administration in community reports.
What Mechanism Research Implies About Repeated High-Dose Use
NAD+'s role in cellular metabolism is broad: it's a cofactor for sirtuins, PARP enzymes, and the electron transport chain. Published Phase 1 NR trials describe a clean safety signal at doses up to 2,000 mg/day for 12 weeks, but no published trial covers months-long IV or subcutaneous NAD+ at the doses community sources describe. The absence of published long-term data is itself a finding regulators and reviewers should note.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Dose-Pause and Discontinuation Patterns
Clinic-published infusion protocols describe a clear pattern: slow or pause the infusion when chest pressure, nausea, or flushing appears, then resume at a reduced rate. Permanent discontinuation is uncommon and is described in community sources as triggered by recurrent severe vagal symptoms or persistent post-infusion fatigue across multiple sessions.
For oral precursors, the published trials' stopping rules were activated for events unrelated to the drug (lab abnormalities not attributable to NR). Mild GI events were managed by dose-reduction in some protocols (Martens et al., PMID 30530683).
For subcutaneous use, community sources describe pause-and-resume patterns when injection-site irritation persists, often combined with site rotation and slower injection speeds.
Hypersensitivity and Allergic-Type Reactions
Published research describes rare hypersensitivity events in IV niacin (the related vitamin) but does not characterize them for NAD+ specifically. Community sources for IV NAD+ describe sparse anaphylaxis-pattern events — these are uncharacterized in trial literature and are reasons sources cite clinic-supervised administration as preferable to at-home self-administration.
Core Supplies for This Protocol
The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking.
Self-reported community data and clinical infusion protocols consistently describe transient chest pressure or tightness during rapid IV NAD+ infusion. The pattern resolves immediately when the infusion is slowed. Published mechanism work attributes it to the rapid increase in cellular NAD+ flux affecting vascular tone.
Is oral NR or NMN safer than IV NAD+?
Published human trials of nicotinamide riboside (Trammell et al., PMID 27721479; Brakedal et al., PMID 36038027) describe single oral doses up to 1,000 mg without serious adverse events. The infusion-specific events — flushing, chest pressure, nausea — are not features of the oral precursor route.
Does NAD+ cause flushing like niacin?
Yes, but less consistently. Niacin-induced flushing is prostaglandin-mediated; NAD+'s flushing pattern in community reports is attributed to the rapid systemic increase in NAD+ flux. Slowing the infusion or splitting the dose reduces flushing severity in community reports.
Are there long-term safety concerns with regular NAD+ use?
The longest published human nicotinamide riboside safety dataset extends to 12 weeks at 1,000 mg/day (Martens et al., PMID 30530683). No safety signals beyond the gastrointestinal-irritation pattern were identified. Longer-term injectable NAD+ data does not exist in the published literature.
When do clinical infusion protocols pause or stop?
Infusion protocols described in community sources and clinic-published procedures slow the infusion rate when chest pressure or nausea appears, then resume at the slower rate. Permanent discontinuation is rare and is described in community sources as triggered by recurrent severe vagal symptoms or persistent post-infusion fatigue.
For educational and research purposes only. This is not medical advice. Injectable NAD+ is not FDA-approved for any indication. Consult a healthcare provider before use.
